Tenjin Tomomi, Miyamoto Seiya
Department of Neuropsychiatry, St. Marianna University School of Medicine.
Nihon Rinsho. 2013 Apr;71(4):660-5.
Blonanserin was developed in Japan in 2008 as an antipsychotic drug. It has high affinity for dopamine D2/3 and serotonin 5-HT2A receptors, but shows low affinity for adrenergic alpha1, histamine H1, and muscarinic M1 receptors. Several short-term double-blind trials demonstrated that blonanserin was well tolerated and had equal efficacy to haloperidol and risperidone in terms of positive symptoms and depressive symptoms in patients with chronic schizophrenia. It was also superior to haloperidol in improving negative symptoms. We have recently reported that blonanserin may improve some types of cognitive function associated with the frontal lobe activity in patients with first-episode schizophrenia. Taken together, blonanserin may be a promising candidate for a first-line antipsychotic for patients with first-episode and chronic schizophrenia.
布南色林于2008年在日本作为一种抗精神病药物研发。它对多巴胺D2/3和5-羟色胺5-HT2A受体具有高亲和力，但对肾上腺素能α1、组胺H1和毒蕈碱M1受体显示出低亲和力。多项短期双盲试验表明，布南色林耐受性良好，在慢性精神分裂症患者的阳性症状和抑郁症状方面与氟哌啶醇和利培酮疗效相当。在改善阴性症状方面，它也优于氟哌啶醇。我们最近报告称，布南色林可能改善首发精神分裂症患者与额叶活动相关的某些类型的认知功能。综上所述，布南色林可能是首发和慢性精神分裂症患者一线抗精神病药物的一个有前景的候选药物。
